RemedyBio is delighted to announce the success of the HEALED Consortium in securing DTIF support of €6.8M as part of a 3-year, €10.5M programme to develop new cell therapies for cancer. The consortium is comprised of RemedyBio as programme lead, aCGT Vector DAC, Trinity College Dublin & St James’s Hospital, and the NUIG’s Genomics Data Science Centre, bringing together deep capabilities in mass-scale functional biology, GMP clinical deployment, clinical and tumour microenvironment expertise in cancer, and molecular data analytics to create a world first in near-patient, personalised, functional cancer therapeutics. Our goal is to enable a new kind of revolutionary immunotherapy to cure incurable cancers. The Disruptive Technologies Innovation Fund (DTIF) is managed and funded through the Department of Enterprise and Innovation (DBEI) in Ireland.
Recommended For You
Ashley Nagle joins RemedyBio as VP, Business Development
Remedy BiologicsMay 21, 2021